Venture capital, Biotech, Cancer therapeutics, Clinical trials, Diagnostics, Digital Health, Drug Delivery, Drug Discovery, Genomics, Health tech, Immunology, Medical Device, Medicine, Neurosciences, Oncology, Therapeutics, Business strategy, IP & Licensing, Market access, Regulatory, Startups, Technology transfer, genetics, biosimilars, gene therapy, molecular diagnostics, stem cells, EMR / EHR, regenerative medicine, neurology, biosimilars, gene therapy, molecular diagnostics, stem cells, consulting
Maurice Perrinjaquet is currently an Associate Director at Navigant Consulting – Life Sciences Strategy. Navigant consults to clients in the Pharmaceutical (e.g. all top 20 pharma companies), Biotech and Medtech industry with a focus on business strategy; market access, pricing and reimbursement; business development, in- and out-licensing opportunities; due diligence; R&D strategy and clinical development; pipeline and portfolio strategy.
Maurice obtained his PhD in Neuroscience at the Karolinska Institute in Stockholm, Sweden and holds a MEng degree in Chemical and Biotech Engineering from the Swiss Federal Institute of Technology in Lausanne, Switzerland.
Maurice has 15 years’ experience in R&D, 5+ years consulting experience in a broad range of therapeutic indications, including a strong focus on oncology, immunology, cardiovascular and orphan diseases, further supported by 2+ years working in a hospital to manage clinical trials for pediatric patients.
Prior to joining Navigant, Maurice was managing clinical trials for the department of Pediatrics of Memorial Sloan Kettering Cancer Center in New York where he overviewed all clinical research activities for the Developmental Therapeutics service. He gained extensive experience in clinical trial management, overseeing phase I, II and III oncology clinical trials for pediatric and young adult patients.
Maurice’s work is focused on developing innovative commercial strategies for clients in the pharmaceutical, specialty pharmaceutical and medical technology industries in both established and emerging markets including US, EU27, Japan and Latin America.
Maurice is fluent in French, Spanish, Catalan, English and German.